Sutro Biopharma Reports Disappointing Earnings Despite Revenue Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy STRO?
Source: seekingalpha
- Earnings Report: Sutro Biopharma's FY GAAP EPS of -$22.49 missed expectations by $7.28, indicating ongoing challenges in profitability despite revenue growth.
- Revenue Growth: The company reported revenue of $102.48M, a 65.2% year-over-year increase, surpassing estimates by $3.3M, reflecting strong market demand for its products.
- Cash Flow Enhancement: Sutro strengthened its cash position with an underwritten offering of 7,868,383 shares at $13.98 per share, generating gross proceeds of $110 million, which is expected to extend its cash runway into at least Q2 2028.
- Strategic Outlook: The anticipated cash flow will support milestones from existing collaborations, and despite profitability challenges, Sutro aims for a positive transformation by 2026.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy STRO?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on STRO
Wall Street analysts forecast STRO stock price to fall
7 Analyst Rating
4 Buy
2 Hold
1 Sell
Moderate Buy
Current: 20.680
Low
8.00
Averages
20.00
High
51.00
Current: 20.680
Low
8.00
Averages
20.00
High
51.00
About STRO
Sutro Biopharma, Inc. is an oncology company engaged in developing site-specific and novel-format antibody drug conjugates (ADCs), enabled by its proprietary integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, XpressCF+. It designs and develops therapeutics using the relevant and potent modalities, including ADCs, bispecific ADCs, immunostimulatory ADCs, and dual conjugate ADCs. Enabled through its XpressCF and XpressCF+ platforms, it has entered multi-target, product-focused collaborations with pharmaceutical and biotechnology companies in the field of oncology, with its ongoing relationships that include licensing to Ipsen, on an exclusive basis, the right to research, develop, manufacture and commercialize STRO-003. STRO-003 is developed for the treatment of solid tumors. Its XpressCF and XpressCF platforms supports Vaxcyte, focused on discovery and development of vaccines for the treatment and prophylaxis of infectious disease.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sutro Biopharma Reports Disappointing Earnings Despite Revenue Growth
- Earnings Report: Sutro Biopharma's FY GAAP EPS of -$22.49 missed expectations by $7.28, indicating ongoing challenges in profitability despite revenue growth.
- Revenue Growth: The company reported revenue of $102.48M, a 65.2% year-over-year increase, surpassing estimates by $3.3M, reflecting strong market demand for its products.
- Cash Flow Enhancement: Sutro strengthened its cash position with an underwritten offering of 7,868,383 shares at $13.98 per share, generating gross proceeds of $110 million, which is expected to extend its cash runway into at least Q2 2028.
- Strategic Outlook: The anticipated cash flow will support milestones from existing collaborations, and despite profitability challenges, Sutro aims for a positive transformation by 2026.
See More
Sutro Biopharma Participates in World ADC Summit
- Participation in World ADC Summit: Sutro Biopharma is participating in the 16th World ADC Summit in London from February 23-26, 2026, showcasing its innovations in antibody-drug conjugates (ADCs) to enhance its visibility and influence in the oncology market.
- Expert Panel Discussions: Chief Scientific Officer Hans-Peter Gerber, Ph.D., will participate in multiple panel discussions, including ADC licensing, partnering, and investment, which is expected to attract attention from industry stakeholders and foster relationships with potential partners.
- Showcasing Innovative Therapies: During the summit, Dr. Gerber will present on the efficacy and safety profiles of dual payload ADCs, particularly focusing on novel linker payloads to overcome resistance mechanisms, potentially piquing investor interest in Sutro's cutting-edge cancer therapies.
- Scientific Publications Release: Following the event, Sutro will publish the content from the discussions in the Scientific Publications section of its website, enhancing its influence in the scientific community and laying the groundwork for future research collaborations.
See More
Sutro Biopharma Prices 7.87M Share Offering at $13.98 Each
- Offering Size: Sutro Biopharma has priced an underwritten offering of 7.87 million shares of common stock at $13.98 per share, which is expected to generate approximately $110 million in gross proceeds before fees and expenses, thereby enhancing the company's financial strength for future growth.
- Use of Proceeds: The net proceeds from this offering will be used alongside existing cash primarily for general corporate purposes, including R&D, clinical development, manufacturing, working capital, and potential acquisitions or investments, aimed at advancing the company's strategic objectives.
- Market Reaction: Following the announcement of the offering, Sutro Biopharma's shares rose 4.5% in premarket trading, reflecting a positive market response to the company's financing plans, which may bolster investor confidence.
- Future Outlook: The closing of this stock offering is expected around February 11, 2026, marking a strategic reset for Sutro in its next-generation ADC pipeline and platform innovation, potentially opening new avenues for growth.
See More
Sutro Biopharma CEO to Present at 44th J.P. Morgan Healthcare Conference
- Conference Appearance: Sutro Biopharma CEO Jane Chung will present at the 44th J.P. Morgan Healthcare Conference on January 15, 2026, at 11:15 AM PT in San Francisco, showcasing the company's innovations in antibody-drug conjugates (ADCs), which is expected to attract investor interest and enhance the company's visibility.
- Live Webcast: The presentation will be accessible via a live webcast on the company's Investor Relations page, with an archived replay available for at least 30 days post-event, ensuring that investors unable to attend can still access key information, thereby enhancing investor engagement and trust.
- Technological Platform: Sutro's next-generation ADC platform aims to deliver single- and dual-payload ADCs by optimizing antibodies, linkers, and payloads, designed to improve drug exposure, reduce side effects, and expand treatable tumor types, demonstrating the company's technological edge in cancer therapy.
- Market Potential: Sutro's ADC pipeline targets large oncology markets with limited treatment options and significant need for improved therapies, indicating the company's strategic positioning to meet unmet medical needs in the oncology sector.
See More
GT Biopharma Advances GTB-3650 Clinical Trial to Cohort 4 with 10μg/kg/day Dosing
- Clinical Advancement: GT Biopharma has advanced its GTB-3650 clinical trial to Cohort 4, where patients are receiving a dosing of 10μg/kg/day, indicating potential efficacy against resistant blood cancers, with further results expected in Q1 2026.
- Safety Confirmation: Six patients across Cohorts 1, 2, and 3 have successfully completed treatment with GTB-3650, establishing the therapy's safety profile at escalating doses without any dose-limiting toxicities, thereby enhancing confidence in the clinical trial.
- Dose Escalation Plan: The trial is designed to include seven cohorts, with plans to enroll two patients per cohort, escalating doses from 1.25μg/kg/day to potentially 100μg/kg/day, demonstrating the company's ongoing commitment to efficacy and patient care.
- Therapeutic Prospects: GT Biopharma is also advancing GTB-5550, with regulatory submission for human trials expected in late December 2025 or January 2026, further expanding its market opportunities in cancer treatment.
See More
GT Biopharma Advances GTB-3650 Clinical Trial to Cohort 4 with 10μg/kg/day Dosing
- Clinical Trial Progress: GT Biopharma has advanced its GTB-3650 clinical trial to Cohort 4, where patients are receiving a dosing of 10μg/kg/day, indicating enhanced safety and potential efficacy in combating resistant blood cancers.
- Treatment Protocol Optimization: The therapy follows a continuous infusion schedule structured as two-week treatment periods followed by two-week rest intervals, which is expected to improve patient adherence and treatment outcomes over a four-month duration.
- Market Potential: Targeting CD33-positive acute myeloid leukemia and high-risk myelodysplastic syndrome, GTB-3650 represents a significant complement to traditional therapies, potentially unlocking substantial market opportunities for the company.
- Future Outlook: The company plans to share its next trial update in Q1 2026, and as dosing escalates, GTB-3650 is expected to approach higher efficacy ranges, further advancing its clinical development trajectory.
See More
Sutro Biopharma Reports Disappointing Earnings Despite Revenue Growth
- Earnings Report: Sutro Biopharma's FY GAAP EPS of -$22.49 missed expectations by $7.28, indicating ongoing challenges in profitability despite revenue growth.
- Revenue Growth: The company reported revenue of $102.48M, a 65.2% year-over-year increase, surpassing estimates by $3.3M, reflecting strong market demand for its products.
- Cash Flow Enhancement: Sutro strengthened its cash position with an underwritten offering of 7,868,383 shares at $13.98 per share, generating gross proceeds of $110 million, which is expected to extend its cash runway into at least Q2 2028.
- Strategic Outlook: The anticipated cash flow will support milestones from existing collaborations, and despite profitability challenges, Sutro aims for a positive transformation by 2026.
See More
Sutro Biopharma Participates in World ADC Summit
- Participation in World ADC Summit: Sutro Biopharma is participating in the 16th World ADC Summit in London from February 23-26, 2026, showcasing its innovations in antibody-drug conjugates (ADCs) to enhance its visibility and influence in the oncology market.
- Expert Panel Discussions: Chief Scientific Officer Hans-Peter Gerber, Ph.D., will participate in multiple panel discussions, including ADC licensing, partnering, and investment, which is expected to attract attention from industry stakeholders and foster relationships with potential partners.
- Showcasing Innovative Therapies: During the summit, Dr. Gerber will present on the efficacy and safety profiles of dual payload ADCs, particularly focusing on novel linker payloads to overcome resistance mechanisms, potentially piquing investor interest in Sutro's cutting-edge cancer therapies.
- Scientific Publications Release: Following the event, Sutro will publish the content from the discussions in the Scientific Publications section of its website, enhancing its influence in the scientific community and laying the groundwork for future research collaborations.
See More
Sutro Biopharma Prices 7.87M Share Offering at $13.98 Each
- Offering Size: Sutro Biopharma has priced an underwritten offering of 7.87 million shares of common stock at $13.98 per share, which is expected to generate approximately $110 million in gross proceeds before fees and expenses, thereby enhancing the company's financial strength for future growth.
- Use of Proceeds: The net proceeds from this offering will be used alongside existing cash primarily for general corporate purposes, including R&D, clinical development, manufacturing, working capital, and potential acquisitions or investments, aimed at advancing the company's strategic objectives.
- Market Reaction: Following the announcement of the offering, Sutro Biopharma's shares rose 4.5% in premarket trading, reflecting a positive market response to the company's financing plans, which may bolster investor confidence.
- Future Outlook: The closing of this stock offering is expected around February 11, 2026, marking a strategic reset for Sutro in its next-generation ADC pipeline and platform innovation, potentially opening new avenues for growth.
See More
Sutro Biopharma CEO to Present at 44th J.P. Morgan Healthcare Conference
- Conference Appearance: Sutro Biopharma CEO Jane Chung will present at the 44th J.P. Morgan Healthcare Conference on January 15, 2026, at 11:15 AM PT in San Francisco, showcasing the company's innovations in antibody-drug conjugates (ADCs), which is expected to attract investor interest and enhance the company's visibility.
- Live Webcast: The presentation will be accessible via a live webcast on the company's Investor Relations page, with an archived replay available for at least 30 days post-event, ensuring that investors unable to attend can still access key information, thereby enhancing investor engagement and trust.
- Technological Platform: Sutro's next-generation ADC platform aims to deliver single- and dual-payload ADCs by optimizing antibodies, linkers, and payloads, designed to improve drug exposure, reduce side effects, and expand treatable tumor types, demonstrating the company's technological edge in cancer therapy.
- Market Potential: Sutro's ADC pipeline targets large oncology markets with limited treatment options and significant need for improved therapies, indicating the company's strategic positioning to meet unmet medical needs in the oncology sector.
See More
GT Biopharma Advances GTB-3650 Clinical Trial to Cohort 4 with 10μg/kg/day Dosing
- Clinical Advancement: GT Biopharma has advanced its GTB-3650 clinical trial to Cohort 4, where patients are receiving a dosing of 10μg/kg/day, indicating potential efficacy against resistant blood cancers, with further results expected in Q1 2026.
- Safety Confirmation: Six patients across Cohorts 1, 2, and 3 have successfully completed treatment with GTB-3650, establishing the therapy's safety profile at escalating doses without any dose-limiting toxicities, thereby enhancing confidence in the clinical trial.
- Dose Escalation Plan: The trial is designed to include seven cohorts, with plans to enroll two patients per cohort, escalating doses from 1.25μg/kg/day to potentially 100μg/kg/day, demonstrating the company's ongoing commitment to efficacy and patient care.
- Therapeutic Prospects: GT Biopharma is also advancing GTB-5550, with regulatory submission for human trials expected in late December 2025 or January 2026, further expanding its market opportunities in cancer treatment.
See More
GT Biopharma Advances GTB-3650 Clinical Trial to Cohort 4 with 10μg/kg/day Dosing
- Clinical Trial Progress: GT Biopharma has advanced its GTB-3650 clinical trial to Cohort 4, where patients are receiving a dosing of 10μg/kg/day, indicating enhanced safety and potential efficacy in combating resistant blood cancers.
- Treatment Protocol Optimization: The therapy follows a continuous infusion schedule structured as two-week treatment periods followed by two-week rest intervals, which is expected to improve patient adherence and treatment outcomes over a four-month duration.
- Market Potential: Targeting CD33-positive acute myeloid leukemia and high-risk myelodysplastic syndrome, GTB-3650 represents a significant complement to traditional therapies, potentially unlocking substantial market opportunities for the company.
- Future Outlook: The company plans to share its next trial update in Q1 2026, and as dosing escalates, GTB-3650 is expected to approach higher efficacy ranges, further advancing its clinical development trajectory.
See More
